VivoSim Labs Inc
Research VivoSim Labs Inc (VIVS) on Bullrun: valuation model: 176.0% undervalued, market cap USD 2.76M, P/E 2.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVIVS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal176.0% undervalued
- Market capUSD 2.76M
- P/E2.3
- Financial periodFY2025
- RevenueUSD 144.00K
- Revenue growth32.1%
- Net income-USD 2.49M
- Free cash flow-USD 9.47M
- Gross margin96.5%
Valuation Snapshot
Bullrun's latest valuation model marks VivoSim Labs Inc as 176.0% undervalued; latest market cap is USD 2.76M; P/E is 2.3.
About VivoSim Labs Inc
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.
Frequently asked questions
Is VivoSim Labs Inc overvalued or undervalued?
Bullrun's valuation model currently marks VivoSim Labs Inc as 176.0% undervalued.
What is VivoSim Labs Inc's market cap?
VivoSim Labs Inc's market capitalization is USD 2.76M.
What is VivoSim Labs Inc's P/E ratio?
VivoSim Labs Inc's price-to-earnings (P/E) ratio is 2.3.
What does VivoSim Labs Inc do?
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models;